| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/06/2005 | EP1414817B1 substituted isoindoles and the use thereof |
| 04/06/2005 | EP1353909B1 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents |
| 04/06/2005 | EP1334086B1 Phenoxyphenyl alkane sulfonates |
| 04/06/2005 | EP1289996B1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
| 04/06/2005 | EP1257275B1 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 04/06/2005 | EP1224469B1 Method of screening for inhibitors of asp2 |
| 04/06/2005 | EP0966435B1 Aminoindan derivatives |
| 04/06/2005 | CN1605027A Methods and compositions for treatment of central nervous system disorders |
| 04/06/2005 | CN1604909A Cyclic peptides as g-protein-coupled receptor antagonists |
| 04/06/2005 | CN1604901A Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/06/2005 | CN1604900A 6-aminomorphinane derivatives, method for production and use thereof |
| 04/06/2005 | CN1604898A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds |
| 04/06/2005 | CN1604897A 7-amino-benzothiazole derivatives as adenosine receptor ligands |
| 04/06/2005 | CN1604892A Prodrugs to d-prolines |
| 04/06/2005 | CN1604800A Drug delivery system for conscious sedation |
| 04/06/2005 | CN1604781A Use of desoxypeganine for treating clinical depression |
| 04/06/2005 | CN1604780A Use of rosuvastatin in pre demented states |
| 04/06/2005 | CN1604776A 4-4-alkoxy-3-hydroxyphenyl-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/06/2005 | CN1604772A Transdermal transport of compounds |
| 04/06/2005 | CN1603324A Leavo halogenated salt and its preparation process and use |
| 04/06/2005 | CN1602944A Compound plaster of dahurian angelica root and its preparation method |
| 04/06/2005 | CN1602943A Sobering electuary |
| 04/06/2005 | CN1602877A Pharmaceutical composition for treating somatization disorder and its preparation process |
| 04/06/2005 | CN1602867A Soft capsule preparation of donepezi hydrochloride and its preparation method |
| 04/06/2005 | CN1602857A Orally disintegrating tablet of safflor yellow and its preparation process |
| 04/06/2005 | CN1602845A Fenfluramine hydrochloride drop pills and its preparation method |
| 04/06/2005 | CN1195853C Neurotrophic factor NNT-1 |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195772C Nb heterocyclic 8-modified adenosine derivs. |
| 04/06/2005 | CN1195762C Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and compositions containing same |
| 04/06/2005 | CN1195756C Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195745C Antiviral macrocyclic compounds |
| 04/06/2005 | CN1195743C Dihydro-1, 3, 5-triazine amine derivatives and their therapeutic uses |
| 04/06/2005 | CN1195735C Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/06/2005 | CN1195524C Use of benzenesulfonyl (thio) ureas in combination with beta-receptor retarder for treatment and prophylaxis of dysfunctions of autonomous nervous system |
| 04/06/2005 | CN1195522C Benzodiazepine derivatives |
| 04/06/2005 | CN1195519C A composition of a 5-HT reuptake inhibitor and a h5-HT 1B antagonist or partial agonist |
| 04/06/2005 | CN1195518C Sustained release tablet formulations to treat Parkinson disease |
| 04/06/2005 | CN1195516C Use of fluorinated triazoles for preparing medicine of treating pain |
| 04/06/2005 | CN1195504C Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 04/06/2005 | CN1195503C Transdermal patch and topical compositions comprising propylnorapomorphine |
| 04/06/2005 | CN1195497C Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same |
| 04/06/2005 | CN1195494C Oral liquid mucoadhesive compositions |
| 04/05/2005 | US6875886 Modified PSMA ligands and uses related thereto |
| 04/05/2005 | US6875868 Pteridine compounds for the treatment of psoriasis |
| 04/05/2005 | US6875792 Inhibition of glutamine synthetase; antiswelling and antiepileptic agents |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875775 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 04/05/2005 | US6875774 Central nervous system disorders; cognition activators; gastrointestinal disorders |
| 04/05/2005 | US6875772 [1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists |
| 04/05/2005 | US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors |
| 04/05/2005 | US6875765 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family |
| 04/05/2005 | US6875762 Tetracyclic azepinoindole compounds |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875597 Comprises nucleotide sequences coding sulfotransferase for identifying modulators and designing drug delivery systems |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | US6875447 Analgesics; pain therapy; administering by injection |
| 04/05/2005 | CA2339621C 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 04/05/2005 | CA2276146C Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 04/05/2005 | CA2235138C Reverse-turn mimetics and methods relating thereto |
| 04/05/2005 | CA2141209C Novel pyridyl- and pyrimidylpiperazine derivatives |
| 04/01/2005 | CA2444161A1 A screening method of drug for treatment of neuropathic pain |
| 03/31/2005 | WO2005028477A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors |
| 03/31/2005 | WO2005028466A1 Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |
| 03/31/2005 | WO2005028456A1 Thiazole derivatives as cannabinoid receptor modulators |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028440A1 Novel gamma secretase inhibitors |
| 03/31/2005 | WO2005028438A1 Novel piperidine derivative |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027969A1 Remedy for eye diseases accompanied by optic nerve injuries |
| 03/31/2005 | WO2005027968A1 Remedy for down syndrome |
| 03/31/2005 | WO2005027934A1 Prolyl oligopeptidase inhibitor |
| 03/31/2005 | WO2005027925A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior |
| 03/31/2005 | WO2005027905A1 Pharmaceutical compositions for the treatment of organophosphate poisoning |
| 03/31/2005 | WO2005027901A1 Compositions and methods using same for treating amyloid-associated diseases |
| 03/31/2005 | WO2005027889A1 Visceral pain dulling composition |
| 03/31/2005 | WO2005027870A1 Buccal formulations of galanthamine and uses thereof |
| 03/31/2005 | WO2005027823A2 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) |
| 03/31/2005 | WO2005014007B1 Compounds for the treatment of autoimmune and demyelinating diseases |
| 03/31/2005 | WO2004108141A3 Bach-o-protein coupled receptor releated methods |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2004103356A3 Treatment of emotional dysregulation |
| 03/31/2005 | WO2004098591A3 Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| 03/31/2005 | WO2004097320A3 Thermal energy storage |
| 03/31/2005 | WO2004092172A3 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists |
| 03/31/2005 | WO2004092171A3 Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| 03/31/2005 | WO2004092170A3 Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists |
| 03/31/2005 | WO2004087744A3 Composition and method for nerve regeneration |
| 03/31/2005 | WO2004062625A3 Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| 03/31/2005 | WO2004009026A8 Cholinergic therapy for individuals with learning disabilities |
| 03/31/2005 | WO2003091243A8 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070718 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |